Adverum is a clinical-stage gene therapy company targeting unmet medical need in ocular and rare diseases. We develop gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Our core capabilities include clinical development, novel vector discovery, and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices (cGMP) quality control. Our team has extensive clinical development experience and is laser-focused on advancing novel gene therapies for patients. Source
No articles found.
Minerva Neurosciences, Inc. (NASDAQ: NERV) is a clinical-stage biopharmaceutical c...
Minerva Neurosciences, Inc. (NASDAQ: NERV) is a...
Applied Science Products operates Advanced Plasma Products, Inc., a science and en...
Applied Science Products operates Advanced Plas...
Novartis is reimagining medicine to improve and extend peoples lives. As a leadin...
Novartis is reimagining medicine to improve and...
Aeglea a clinical-stage biotechnology company that engineers next generation human...
Aeglea a clinical-stage biotechnology company t...
Axogen (AXGN) is a global leader in innovative surgical solutions for peripheral n...
Axogen (AXGN) is a global leader in innovative ...
At Delee, we aim to radically change the way cancer is detected, monitored and tre...
At Delee, we aim to radically change the way ca...
Orchard Therapeutics is a fully integrated commercial-stage biopharmaceutical comp...
Orchard Therapeutics is a fully integrated comm...
Join the National Investor Network and get the latest information with your interests in mind.